VolitionRx Initiates Clinical Trial with German Cancer Research Center (DKFZ) to Evaluate NuQ(R) Blood Test for Pancreatic Cancer 750-patient study will assess VolitionRx's proprietary Nucleosomics® platform for non-invasive detection of pancreatic cancer

This collaboration follows VolitionRx's announcements last year of highly encouraging data from two preliminary studies for pancreatic cancer detection. Results from a 59-patient trial with Lund University in Sweden, published in the journal Clinical Epigenetics, demonstrated a detection rate of 92% (23 of 25) of pancreatic cancer cases at 100% specificity using a panel of four NuQ® biomarker assays and the classical CA19-9 cancer biomarker. A second study with Hvidovre Hospital, University of Copenhagen in Denmark, demonstrated that a panel of two NuQ® biomarker assays and the classical cancer marker CEA (carcino-embryonic antigen) in an age and gender adjusted panel detected 95% (19 out of 20) of pancreatic cancers at 84% specificity.